Literature DB >> 26405601

Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery.

Olesja Fornara1, Jenny Odeberg1, Nina Wolmer Solberg1, Charlotte Tammik1, Petra Skarman1, Inti Peredo2, Giuseppe Stragliotto3, Afsar Rahbar1, Cecilia Söderberg-Nauclér1.   

Abstract

Patients with glioblastoma multiforme (GBM) are immunosuppressed and have a broad range of immunological defects in both innate and adaptive immune responses. GBMs are frequently infected with human cytomegalovirus (HCMV), a virus capable of causing immunosuppression. In 42 HCMV-positive GBM patients in a clinical trial (VIGAS), we investigated T-cell phenotypes in the blood and assessed their relation to survival. Blood was collected before and 3, 12, and 24 weeks after surgery, and the frequency of T-cell subsets was compared with that in 26 age-matched healthy controls. GBM patients had lower levels of CD3 cells than the controls, but had significantly higher levels of CD4+CD28- T cells before and 3 and 12 weeks after surgery and increased levels of CD4+CD57+ and CD4+CD57+CD28+ T cells at all-time points. These T-cell subsets were associated with both immunosenescence and HCMV infection. GBM patients also had higher levels of γδ T cells at all-times after surgery and lower levels of CD4+CD25+ cells before and 3 weeks after surgery than healthy controls. Overall survival was significantly shorter in patients with higher levels of CD4+CD28- T cells (p = 0.025), CD4+CD57+ T (p = 0.025) cells, and CD4+CD28-CD57+CD28- T cells (p < 0.0004) at 3 weeks after surgery. Our findings indicate that signs of immunosenescence in the CD4+ compartment are associated with poor prognosis in patients with HCMV-positive GBMs and may reflect the HCMV activity in their tumors.

Entities:  

Keywords:  T cells; cytomegalovirus; glioblastoma; immunosenescence; survival

Year:  2015        PMID: 26405601      PMCID: PMC4570117          DOI: 10.1080/2162402X.2015.1036211

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  52 in total

Review 1.  A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients.

Authors:  Michiel G H Betjes; Ruud W J Meijers; Lucia E A de Wit; Nicolle H R Litjens
Journal:  J Nephrol       Date:  2012 Mar-Apr       Impact factor: 3.902

2.  The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire.

Authors:  Batoul Pourgheysari; Naeem Khan; Donna Best; Rachel Bruton; Laxman Nayak; Paul A H Moss
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

Review 3.  CD4+ CD28 null T cells in coronary artery disease: when helpers become killers.

Authors:  Ingrid E Dumitriu; Ernesto Trallero Araguás; Christina Baboonian; Juan Carlos Kaski
Journal:  Cardiovasc Res       Date:  2008-09-25       Impact factor: 10.787

Review 4.  CD28 extinction in human T cells: altered functions and the program of T-cell senescence.

Authors:  Abbe N Vallejo
Journal:  Immunol Rev       Date:  2005-06       Impact factor: 12.988

Review 5.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

6.  Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10.

Authors:  Juliet V Spencer; Kristen M Lockridge; Peter A Barry; Gaofeng Lin; Monica Tsang; Mark E T Penfold; Thomas J Schall
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes.

Authors:  Taku Kobayashi; Susumu Okamoto; Yuko Iwakami; Atsushi Nakazawa; Tadakazu Hisamatsu; Hiroshi Chinen; Nobuhiko Kamada; Toshio Imai; Hidemi Goto; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2007-07       Impact factor: 5.325

8.  Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection.

Authors:  Ester M M van Leeuwen; Ester B M Remmerswaal; Mireille T M Vossen; Ajda T Rowshani; Pauline M E Wertheim-van Dillen; René A W van Lier; Ineke J M ten Berge
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

9.  Imbalances in T cell subpopulations in human gliomas.

Authors:  M K Bhondeley; R D Mehra; N K Mehra; A K Mohapatra; P N Tandon; S Roy; V Bijlani
Journal:  J Neurosurg       Date:  1988-04       Impact factor: 5.115

Review 10.  Novel approaches and mechanisms of immunotherapy for glioblastoma.

Authors:  Meenakshi Hegde; Kevin J Bielamowicz; Nabil Ahmed
Journal:  Discov Med       Date:  2014-03       Impact factor: 2.970

View more
  13 in total

Review 1.  Immunosenescence: a key player in cancer development.

Authors:  Jingyao Lian; Ying Yue; Weina Yu; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-11-10       Impact factor: 17.388

Review 2.  The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer.

Authors:  Xiao-Hua Luo; Qingda Meng; Martin Rao; Zhenjiang Liu; Georgia Paraschoudi; Ernest Dodoo; Markus Maeurer
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

Review 3.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

Review 4.  Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.

Authors:  Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad
Journal:  Br J Cancer       Date:  2022-06-04       Impact factor: 9.075

Review 5.  CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

Authors:  Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2021-06-14       Impact factor: 12.531

Review 6.  The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme.

Authors:  Amin Daei Sorkhabi; Aila Sarkesh; Hossein Saeedi; Faroogh Marofi; Mahnaz Ghaebi; Nicola Silvestris; Behzad Baradaran; Oronzo Brunetti
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

Review 7.  T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies.

Authors:  Danay Saavedra; Beatriz Garcia; Agustin Lage
Journal:  Front Immunol       Date:  2017-02-14       Impact factor: 7.561

Review 8.  Does Regular Exercise Counter T Cell Immunosenescence Reducing the Risk of Developing Cancer and Promoting Successful Treatment of Malignancies?

Authors:  James E Turner; Patricia C Brum
Journal:  Oxid Med Cell Longev       Date:  2017-07-02       Impact factor: 6.543

9.  Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated γδ T lymphocytes.

Authors:  Gabriela V Salamone; Carolina C Jancic; David A Rosso; Micaela Rosato; Juan Iturrizaga; Nazareno González; Carolina M Shiromizu; Irene A Keitelman; Juan V Coronel; Fernando D Gómez; María M Amaral; Alejandra T Rabadan
Journal:  J Neurooncol       Date:  2021-06-14       Impact factor: 4.130

Review 10.  Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Authors:  Yogesh R Suryawanshi; Autumn J Schulze
Journal:  Viruses       Date:  2021-07-02       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.